These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14504374)

  • 1. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Jenner P
    Neurology; 2003 Sep; 61(6 Suppl 3):S4-11. PubMed ID: 14504374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
    Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    Iravani MM; Jackson MJ; Kuoppamäki M; Smith LA; Jenner P
    J Neurosci; 2003 Oct; 23(27):9107-15. PubMed ID: 14534244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.
    Kuoppamäki M; Al-Barghouthy G; Jackson MJ; Smith LA; Quinn N; Jenner P
    J Neural Transm (Vienna); 2007 Sep; 114(9):1147-53. PubMed ID: 17446998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.
    Jenner P
    Parkinsonism Relat Disord; 2003 Jan; 9(3):131-7. PubMed ID: 12573867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
    Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
    Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.